IRVINE, CA and UNIONDALE, NY and LIEGE, BELGIUM--(Marketwired - July 29, 2013) - MDxHealth SA (NYSE Euronext: MDXH) and Bostwick Laboratories, Inc. today announced that they have entered into a marketing agreement to commercialize MDxHealth's ConfirmMDx for Prostate Cancer test. Bostwick Laboratories is a national, full-service laboratory specializing in anatomic and clinical pathology, with a focus on uropathology. The agreement provides MDxHealth with access to one of the largest urology networks in the United States.
"We are excited to partner with Bostwick Laboratories, a recognized leader in urologic anatomic pathology services with a focus on improving patient care and outcomes. This marketing agreement provides their extensive customer base with access to our ConfirmMDx for Prostate Cancer test" said Dr. Jan Groen, CEO of MDxHealth. "With their national reach and strong reputation, Bostwick Laboratories is an ideal partner to help us continue building upon the momentum we have achieved to date, raising awareness and access to ConfirmMDx within the urology community."
"We are pleased to announce our partnership with MDxHealth and the addition of ConfirmMDx for Prostate Cancer to our portfolio of testing services. This epigenetic test provides additional clinical utility for our urology clients and their patients," stated Martin Stefanelli, CEO of Bostwick Laboratories. "We are committed to consistently providing new testing that enhances patient care and helps physicians make better treatment decisions and we believe the ConfirmMDx test delivers on that promise."
About ConfirmMDx for Prostate Cancer
Over 975,000 American men receive a negative prostate biopsy result each year, though approximately 25% of these men may still harbor occult prostate cancer. This well-documented risk of undetected cancer, often with clinically significant Gleason scores, leads to a high rate of repeat biopsies with greater than 40% of men receiving at least one repeat biopsy, and many receiving a 3rd and 4th biopsy. Today's gold standard diagnostic approach is the prostate biopsy procedure, collecting 10-12 needle core biopsy samples; however this sampling represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is an epigenetic assay to help urologists distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test is able to detect an epigenetic field effect or "halo" associated with the cancerization process at the DNA level. This molecular "halo" around a cancer lesion can be present despite having a normal appearance under the microscope. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and rule in high-risk patients who may require repeat biopsies and potential treatment.
About Bostwick Laboratories
Bostwick Laboratories provides anatomic and clinical pathology laboratory services specializing in the monitoring and diagnosis of cancer. Bostwick Laboratories is a leader in urologic pathology with expertise and a growing presence in the women's health, dermatology, gastroenterology, nephrology and hematology sectors of the anatomic pathology market. Bostwick Laboratories and its staff of board-certified, internationally recognized pathologists provide definitive diagnoses and the most technologically advanced testing available to help physicians and patients choose the best course of treatment. For more information, visit our website at www.bostwicklaboratories.com.
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. By applying patented DNA methylation platform and biomarkers, MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. For more information visit www.mdxhealth.com.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
To access the PDF version, please click here: http://hugin.info/137314/R/1719295/572191.pdf.